Bicycle therapeutics announces collaboration with the german cancer research center, to discover and develop wholly owned bicycle® radio conjugates for a range of oncology targets

Cambridge, england, & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that it has entered into a collaboration with the german cancer research center (dkfz), to develop and discover bicycle® radio conjugates (brcs) for a range of oncology targets. founded in 1964, dkfz is the largest biomedical research institution i.
BCYC Ratings Summary
BCYC Quant Ranking